Brady K. Atwood

Brady K. Atwood

Auto-generated profile, based on publicly available information

Brady K. Atwood

Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2010 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
BABrady K Atwood
Brady K Atwood
KMKen Mackie
Ken Mackie

7 January 2011 in BMC Genomics
Verified
Journal Article
Open access
PDF file
BABrady K Atwood
Brady K Atwood
JLJacqueline Lopez
Jacqueline Lopez
JWJames Wager-Miller
James Wager-Miller
KMKen Mackie
Ken Mackie
ASAlex Straiker
Alex Straiker
Background: G protein coupled receptors (GPCRs) are one of the most widely studied gene superfamilies. Thousands of GPCR research studies have utilized heterologous expression systems such as human embryonic kidney cells (HEK293). Though often treated as 'blank slates', these cell lines nevertheless endogenously express GPCRs and related signaling proteins. The outcome of a given GPCR study can be profoundly influenced by this largely unknown complement of receptors and/or signaling proteins. Little easily accessible information exists that describes the expression profiles of the GPCRs in cell lines. What is accessible is often limited in scope - of the hundreds of GPCRs and related proteins, one is unlikely to find information on expression of more than a dozen proteins in a given cell line. Microarray technology has allowed rapid analysis of mRNA levels of thousands of candidate genes, but though often publicly available, the results can be difficult to efficiently access or even to interpret.Results: To bridge this gap, we have used microarrays to measure the mRNA levels of a comprehensive profile of non-chemosensory GPCRs and over a hundred GPCR signaling related gene products in four cell lines frequently used for GPCR research: HEK293, AtT20, BV2, and N18.Conclusions: This study provides researchers an easily accessible mRNA profile of the endogenous signaling repertoire that these four cell lines possess. This will assist in choosing the most appropriate cell line for studying GPCRs and related signaling proteins. It also provides a better understanding of the potential interactions between GPCRs and those signaling proteins.

1 June 2016 in Neuron
Verified
Journal Article
Closed access
CGChristina M. Gremel
Christina M. Gremel
JCJessica H. Chancey
Jessica H. Chancey
BABrady K. Atwood
Brady K. Atwood
GLGuoxiang Luo
Guoxiang Luo
RNRachael Neve
Rachael Neve
RCRui M. Costa
Rui M. Costa

19 May 2010 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
BABrady K Atwood
Brady K Atwood
JHJohn Huffman
John Huffman
ASAlex Straiker
Alex Straiker
KMKen Mackie
Ken Mackie
Background and purpose: ‘Spice’ is an herbal blend primarily marketed in Europe as a mild hallucinogen with prominent cannabis‐like effects and as a legal alternative to cannabis. However, a recent report identified a number of synthetic additives in samples of ‘Spice’. One of these, the indole derivative JWH018, is a ligand for the cannabinoid receptor 1 (CB1) cannabinoid receptor and inhibits cAMP production in CB1receptor‐expressing CHO cells. Other effects of JWH018 on CB1receptor‐mediated signalling are not known, particularly in neurons. Here we have evaluated the signalling pathways activated by JWH018 at CB1receptors.Experimental approach: We investigated the effects of JWH018 on neurotransmission in cultured autaptic hippocampal neurons. We further analysed its activation of ERK1/2 mitogen activated protein kinase (MAPK) and internalization of CB1receptors in HEK293 cells stably expressing this receptor.Key results: In cultured autaptic hippocampal neurons, JWH018 potently inhibited excitatory postsynaptic currents (IC50= 14.9 nM) in a concentration‐ and CB1receptor‐dependent manner. Furthermore, it increased ERK1/2 MAPK phosphorylation (EC50= 4.4 nM). We also found that JWH018 potently induced rapid and robust CB1receptor internalization (EC50= 2.8 nM;t1/2= 17.3 min).Conclusions and implications: JWH018, a prominent component of several herbal preparations marketed for their psychoactivity, is a potent and effective CB1receptor agonist that activates multiple CB1receptor signalling pathways. Thus, it is likely that the subjective effects of ‘Spice’ are due to activation of cannabinoid CB1receptors by JWH018, added to this herbal preparation.

15 June 2022 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
KRKaitlin C. Reeves
Kaitlin C. Reeves
NSNikhil Shah
Nikhil Shah
BMBraulio Muñoz
Braulio Muñoz
BABrady K. Atwood
Brady K. Atwood
Opioids mediate their effectsviaopioid receptors: mu, delta, and kappa. At the neuronal level, opioid receptors are generally inhibitory, presynaptically reducing neurotransmitter release and postsynaptically hyperpolarizing neurons. However, opioid receptor-mediated regulation of neuronal function and synaptic transmission is not uniform in expression pattern and mechanism across the brain. The localization of receptors within specific cell types and neurocircuits determine the effects that endogenous and exogenous opioids have on brain function. In this review we will explore the similarities and differences in opioid receptor-mediated regulation of neurotransmission across different brain regions. We discuss how future studies can consider potential cell-type, regional, and neural pathway-specific effects of opioid receptors in order to better understand how opioid receptors modulate brain function.

1 February 2012 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
BABrady K. Atwood
Brady K. Atwood
JWJames Wager-Miller
James Wager-Miller
CHChristopher Haskins
Christopher Haskins
ASAlex Straiker
Alex Straiker
KMKen Mackie
Ken Mackie
Receptor internalization increases the flexibility and scope of G protein-coupled receptor (GPCR) signaling. CB1 and CB2 cannabinoid receptors undergo internalization after sustained exposure to agonists. However, it is not known whether different agonists internalize CB2 to different extents. Because CB2 is a promising therapeutic target, understanding its trafficking in response to different agonists is necessary for a complete understanding of its biology. Here we profile a number of cannabinoid receptor ligands and provide evidence for marked functional selectivity of cannabinoid receptor internalization. Classic, aminoalkylindole, bicyclic, cannabilactone, iminothiazole cannabinoid, and endocannabinoid ligands varied greatly in their effects on CB1 and CB2 trafficking. Our most striking finding was that (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo-[1,2,3-d,e]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone (WIN55,212-2) (and other aminoalkylindoles) failed to promote CB2 receptor internalization, whereas 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol (CP55,940) robustly internalized CB2 receptors. Furthermore, WIN55,212-2 competitively antagonized CP55,940-induced CB2 internalization. Despite these differences in internalization, both compounds activated CB2 receptors as measured by extracellular signal-regulated kinase 1/2 phosphorylation and recruitment of β-arrestin2 to the membrane. In contrast, whereas CP55,940 inhibited voltage-gated calcium channels via CB2 receptor activation, WIN55,212-2 was ineffective on its own and antagonized the effects of CP55,940. On the basis of the differences we found between these two ligands, we also tested the effects of other cannabinoids on these signaling pathways and found additional evidence for functional selectivity of CB2 ligands. These novel data highlight that WIN55,212-2 and other cannabinoids show strong functional selectivity at CB2 receptors and suggest that different classes of CB2 ligands may produce diverse physiological effects, emphasizing that each class needs to be separately evaluated for therapeutic efficacy.